Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. has established a Strategic and ESG Committee under its board of directors, formalizing the committee’s terms of reference to guide its structure and operations. The document outlines the committee’s general provisions, composition, responsibilities, procedural rules and the duties of its chairman, signaling a more systematic approach to strategy and environmental, social and governance oversight, which may strengthen governance practices and align the company with rising ESG expectations among investors and regulators.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company focused on the research, development and commercialization of innovative medicines. The company operates in the life sciences and healthcare sector, with a strategic emphasis on long-term growth, corporate governance and sustainable development initiatives.
Average Trading Volume: 3,152,085
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.33B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.